Meeting
2016 ASCO Annual Meeting
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
Authors
Vera Hirsh
McGill University, Montreal, QC, Canada
Vera Hirsh , James Chih-Hsin Yang , Eng-Huat Tan , Ken O'Byrne , Li Zhang , Michael J. Boyer , Tony Mok , Ki Hyeong Lee , Shun Lu , Yuankai Shi , Sang-We Kim , Janessa J. Laskin , Dong-Wan Kim , Catherine Dubos Arvis , Karl Kölbeck , Martin H. Schuler , Dan Massey , Angela Maerten , Luis Paz-Ares , Keunchil Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01466660
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9046)
DOI
10.1200/JCO.2016.34.15_suppl.9046
Abstract #
9046
Poster Bd #
369
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
First Author: Hiroshige Yoshioka
Poster
2023 ASCO Annual Meeting
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
First Author: Xiuning Le
Poster
2022 ASCO Annual Meeting
Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.
First Author: Gongyan Chen
Poster
2019 ASCO Annual Meeting
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).
First Author: Alexis B. Cortot